Document Detail

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
MedLine Citation:
PMID:  22056855     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC).
METHODS: A panel of expert oncologists, pulmonologists and radiologists reviewed the available data to identify predictive factors for PH in order to help guide physicians using bevacizumab in patients with NSCLC.
RESULTS: Patients with NSCLC are at an increased risk of PH owing to the underlying disease process. Patients with squamous histology and/or a history of grade ≥ 2 haemoptysis (≥ 2.5 ml per event) should not receive bevacizumab. No clinical or radiological features (including cavitation and central tumour location) reliably predict severe PH in bevacizumab-treated patients. Major blood vessel infiltration and bronchial vessel infiltration, encasement and abutting may predict PH; however, standardised radiological criteria for defining infiltration have not been established. Eligibility for bevacizumab is not affected by patient age, performance status or anticoagulation or antiplatelet therapy.
CONCLUSIONS: An individualised risk-benefit assessment should be undertaken in all patients with NSCLC in whom bevacizumab is being considered. Further research is required to elucidate the mechanisms underlying PH and the clinical risk factors.
M Reck; F Barlesi; L Crinò; C I Henschke; D Isla; S Stiebeler; D R Spigel
Related Documents :
22244295 - Impact of physician-assisted triage on timing of antibiotic delivery in patients admitt...
15791965 - Interstitial cystitis and endometriosis in patients with chronic pelvic pain: the "evil...
21653295 - Use of a simple criteria set for guiding echocardiography in nosocomial staphylococcus ...
24995965 - Neurosurgical treatment for dystonia: long-term outcome in a case series of 80 patients.
15274515 - A questionnaire on sleep and mental disorders in parkinson's disease (qsmdpd): developm...
15382125 - Clinical outcome of hbeag-negative chronic hepatitis b in relation to virological respo...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2011-11-04
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  23     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-25     Completed Date:  2012-09-07     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1111-20     Citation Subset:  IM    
Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / adverse effects,  therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*,  therapeutic use
Carcinoma, Non-Small-Cell Lung / complications,  diagnosis,  drug therapy*
Expert Testimony
Forecasting / methods
Hemorrhage / chemically induced,  diagnosis*,  etiology,  therapy*
Lung Diseases / chemically induced,  diagnosis*,  etiology,  therapy*
Lung Neoplasms / complications,  diagnosis,  drug therapy*
Risk Factors
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized...
Next Document:  Dosimetric evaluation of breast radiotherapy in a dynamic phantom.